European Journal of Surgical Oncology
Volume 36, Issue 7 , Pages 657-662 , July 2010

K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer

  • H. Chen

      Affiliations

    • Department of Hepatobiliary & Pancreatic Oncology, Cancer Hospital, Fudan University, Shanghai, China
    • ,
  • H. Tu

      Affiliations

    • State Key laboratory of Oncogenes and Related Genes, Cancer Institute of Shanghai, Jiao-Tong University, Shanghai, China
    • ,
  • Z.Q. Meng

      Affiliations

    • Department of Hepatobiliary & Pancreatic Oncology, Cancer Hospital, Fudan University, Shanghai, China
    • ,
  • Z. Chen

      Affiliations

    • Department of Hepatobiliary & Pancreatic Oncology, Cancer Hospital, Fudan University, Shanghai, China
    • ,
  • P. Wang

      Affiliations

    • Department of Hepatobiliary & Pancreatic Oncology, Cancer Hospital, Fudan University, Shanghai, China
    • ,
  • L.M. Liu

      Affiliations

    • Department of Hepatobiliary & Pancreatic Oncology, Cancer Hospital, Fudan University, Shanghai, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 021 64175590x1308; fax: +86 021 64437657.

,Accepted 10 May 2010.

References 

  1. Simon B, Printz H. Epidemiological trends in pancreatic neoplasias. Dig Dis. 2001;19(1):6–14
  2. Castells A, Puig P, Mora J, et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol. 1999;17(2):578–584
  3. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22(18):3776–3783
  4. Michaud DS, Giovannucci E, Willett WC, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. J Am Med Assoc. 2001;286(8):92–99
  5. Iodice S, Gandini S, Maisonneuve P, et al. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393(4):535–545
  6. Krishnan S, Rana V, Janjan NA, et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer. 2006;107(11):2589–2596
  7. Engelken FJ, Bettschart V, Rahman MQ, et al. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol. 2003;29(4):368–373
  8. Koom WS, Seong J, Kim YB, et al. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73(4):1148–1154
  9. Murphy NC, Scarlett CJ, Kench JG, et al. Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. Br J Cancer. 2008;98(3):537–541
  10. Wang P, Fan J, Chen Z, et al. Low-level expression of Smad7 correlates with lymph node metastasis and poor prognosis in patients with pancreatic cancer. Ann Surg Oncol. 2009;16(4):826–835
  11. Jiao L, Zhu J, Hassan MM, et al. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients in relation to cigarette smoking. Pancreas. 2007;34(1):55–62
  12. Nakata K, Ohuchida K, Naqai E, et al. Lmo2 is a novel predictive marker of a better prognois in pancrestic cancer. Neoplasia. 2009;11(7):712–719
  13. Maire F, Micard S, Hammel P, et al. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer. 2002;87(5):551–554
  14. Däbritz J, Preston Ro, Hanfler J, et al. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer correlation with clinical features and carbohydrate antigen 19-9. Pancreas. 2009;38(5):534–541
  15. Wang M, Block TM, Steel L, et al. Preferential isolation of fragmented DNA enhances the detection of circulating mutated K-ras DNA. Clin Chem. 2004;50(1):211–213
  16. Mora J, Urgell E, Farré A, et al. Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer. Clin Chem. 2006;52(7):1448–1449
  17. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–650
  18. Uemura T, Hibi K, Kaneko T, et al. Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. J Gastroenterol. 2004;39(1):56–60
  19. Olsen CC, Schefter TE, Chen H, et al. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol. 2009;32(2):115–121
  20. Salek C, Benesova L, Zavoral M, et al. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol. 2007;13(27):3714–3720
  21. Slebos RJ, Hoppin JA, Tolbert PE, et al. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomarkers Prev. 2000;9(11):1223–1232
  22. Mulcahy HE, Lyautey J, Lederrey C, et al. A prospective study of k-ras mutation in plasma of pancreatic cancer patients. Clin Cancer Res. 1998;4(2):271–275
  23. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143(2):545–554
  24. Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994;54(6):1556–1560
  25. Scarpa A, Capelli P, Villaneuva A, et al. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int J Cancer. 1994;57(2):167–171
  26. Berrozpe G, Schaeffer J, Peinado MA, et al. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer. 1994;58(2):185–191
  27. Yamada T, Nakamori S, Ohzato H, et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res. 1998;4(6):1527–1532
  28. Salek C, Minarikova P, Benesova L, et al. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. Anticancer Res. 2009;29(5):1803–1810
  29. Niedergethmann M, Rexin M, Hildenbrand R, et al. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol. 2002;26(12):1578–1587
  30. Kawesha A, Ghaneh P, Andrén-Sandberg A, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2000;89(6):469–474

PII: S0748-7983(10)00122-8

doi: 10.1016/j.ejso.2010.05.014

European Journal of Surgical Oncology
Volume 36, Issue 7 , Pages 657-662 , July 2010

Article Tools

* Image Usage & Resolution